Lilly’s Necitumumab Gains FDA Panel Blessing For Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, post-marketing safety study likely to be required on use of prophylactic anticoagulation to head off thromboembolic events with the anti-EGFR agent.